Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study.
[esophageal adenocarcinoma]
Barrett
's
esophagus
(
BE
)
is
associated
with
an
increased
risk
of
developing
esophageal
adenocarcinoma
(
EAC
)
.
Patients
with
a
known
diagnosis
of
BE
are
usually
advised
to
participate
in
an
endoscopic
surveillance
program
,
but
its
clinical
value
is
unproven
.
Our
objective
was
to
compare
patients
participating
in
a
surveillance
program
for
BE
before
EAC
diagnosis
with
those
not
participating
in
such
a
program
,
and
to
determine
predictive
factors
for
mortality
from
EAC
.
All
patients
diagnosed
with
EAC
between
1999
and
2009
were
identified
in
the
nationwide
Netherlands
Cancer
Registry
.
These
data
were
linked
to
Pathologisch-
Anatomisch
Landelijk
Geautomatiseerd
Archief
,
the
Dutch
Pathology
Registry
.
Prior
surveillance
was
evaluated
,
and
multivariable
Cox
proportional
hazards
regression
analysis
was
performed
to
identify
predictors
for
all-cause
mortality
at
2
-
year
and
5
-
year
follow-up
.
In
total
,
9
,
780
EAC
patients
were
included
.
Of
these
,
791
(
8
%
)
patients
were
known
with
a
prior
diagnosis
of
BE
,
of
which
452
(
57
%
)
patients
participated
in
an
adequate
endoscopic
surveillance
program
,
120
(
15
%
)
patients
in
an
inadequate
program
,
and
219
(
28
%
)
patients
had
a
prior
BE
diagnosis
without
participating
.
Two
-
year
(
and
five
-
year
)
mortality
rates
were
lower
in
patients
undergoing
adequate
surveillance
(
adjusted
hazard
ratio
(
HR
)
=
0
.
79
,
95
%
confidence
interval
(
CI
)
=
0
.
64
-
0
.
92
)
when
compared
with
patients
with
a
prior
BE
diagnosis
who
were
not
participating
.
Other
factors
associated
with
lower
mortality
from
EAC
were
lower
tumor
stage
(
stage
I
vs
.
IV
,
HR
=
0
.
19
,
95
%
CI
=
0
.
16
-
0
.
23
)
and
combining
surgery
with
neoadjuvant
chemo
/
radiotherapy
(
HR
=
0
.
66
,
95
%
CI
=
0
.
58
-
0
.
76
)
.
Participation
in
a
surveillance
program
for
BE
,
but
only
if
adequately
performed
,
reduces
mortality
from
EAC
.
Nevertheless
,
it
remains
to
be
determined
whether
such
a
program
is
cost-effective
,
as
more
than
90
%
of
all
EAC
patients
were
not
known
to
have
BE
before
diagnosis
.
Diseases
Validation
Diseases presenting
"an increased risk of developing esophageal adenocarcinoma"
symptom
esophageal adenocarcinoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom